[NCI CIRB] A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
The purpose of this study is to compare the effects of three drugs, crizotinib, cabozantinib and savolitinib, to see if any of them slow tumor growth in advanced kidney cancer better then the standard treatment, sunitinib.
18 years or older with confirmed advanced kidney cancer. Further tests, procedures, and exams will be done to further confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
For as long as the participant is seeing benefit from the study drug
Knight Clinical Trials